capital · May 13, 2026
Kura Oncology Reports $5.8 Million in Q1 2026 Product Revenue
Share the canonical public link.
Kura Oncology reported $5.8 million in net product revenue for Q1 2026 on May 12, 2026. The company also recorded $12.5 million in collaboration revenue from its agreement with Kyowa Kirin, down from $14.1 million in Q1 2025. Kura ended the quarter with $580.8 million in cash, cash equivalents, and short-term investments. Kura anticipates $180 million in additional collaboration payments to fund the ziftomenib AML program through 2028.
The body describes quarterly financial results with moderate impact, including a modest $5.8M product revenue increase and a strong $580.8M cash position, but lacks company-defining events like major funding or pivots, justifying a mid-tier 'notable' score without inflation. It contains numerous verifiable specifics: companies (Kura Oncology, Kyowa Kirin), dollar amounts ($5.8M, $12.5M, $14.1M, $580.8M, $180M), dates (Q1 2026, May 12, 2026, Q1 2025, through 2028), and program name (ziftomenib AML), exceeding 3 concrete facts. The analysis field is explicitly '(none)', providing no strategic insight beyond the headline and body facts.